[go: up one dir, main page]

WO1988007365A3 - Support de medicaments a bio-adhesion pour absorption endotheliale et epitheliale et localisation d'agents therapeutiques et de diagnostic - Google Patents

Support de medicaments a bio-adhesion pour absorption endotheliale et epitheliale et localisation d'agents therapeutiques et de diagnostic Download PDF

Info

Publication number
WO1988007365A3
WO1988007365A3 PCT/US1988/001096 US8801096W WO8807365A3 WO 1988007365 A3 WO1988007365 A3 WO 1988007365A3 US 8801096 W US8801096 W US 8801096W WO 8807365 A3 WO8807365 A3 WO 8807365A3
Authority
WO
WIPO (PCT)
Prior art keywords
carrier
endothelial
vascular
diagnostic
endothelium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1988/001096
Other languages
English (en)
Other versions
WO1988007365A1 (fr
WO1988007365A2 (fr
Inventor
David F Ranney
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25671864&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO1988007365(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Priority to AT88903702T priority Critical patent/ATE90554T1/de
Priority to EP88903702A priority patent/EP0352295B2/fr
Priority to DE3881881T priority patent/DE3881881T3/de
Priority to CA000565119A priority patent/CA1324080C/fr
Publication of WO1988007365A1 publication Critical patent/WO1988007365A1/fr
Publication of WO1988007365A2 publication Critical patent/WO1988007365A2/fr
Publication of WO1988007365A3 publication Critical patent/WO1988007365A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5115—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/829—Liposomes, e.g. encapsulation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
    • Y10T428/2984—Microcapsule with fluid core [includes liposome]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
    • Y10T428/2989—Microcapsule with solid core [includes liposome]

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Préparation et expérimentation in vivo de revêtements de surface et de matériaux matriciels qui, lorsqu'ils contiennent les supports de medicaments et d'agents de diagnostic ou qu'ils leurs sont appliqués et sont administrés de façon à permettre un accès vasculaire efficace, provoquent la reconnaisssance par le support de substances déterminantes présentes sur un endothélium normal ou affecté localement, et entraînent les effets in vivo suivants: 1) enveloppement rapide, partiel ou total du support de médicament (ou d'agent de diagnostic); 2) séquestration du support et protection rapide (2 minutes) de l'agent encapsulé de l'épuration vasculaire sanguine lorsque la poche endothéliale qui enveloppe le support est encore en train d'invaginer le compartiment vasculaire; 3) accélération du transport du support à travers l'endothelium vasculaire ou les structures sub-endothéliales vers l'interstice; et 4) amélioration de l'efficacité de migration du médicament (oude l'agent de diagnostic) à travers les barrières endothéliales ou sub-endothéliales, ce qui permet de réduire la dose totale de medicament requise pour obtenir l'effet désiré par rapport à la dose correspondante en agents habituels. Une absorption tissulaire analogue est obtenue pour la migration transepithéliale dans les poumons, la vessie et les intestins.
PCT/US1988/001096 1987-04-01 1988-03-30 Support de medicaments a bio-adhesion pour absorption endotheliale et epitheliale et localisation d'agents therapeutiques et de diagnostic Ceased WO1988007365A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AT88903702T ATE90554T1 (de) 1987-04-01 1988-03-30 Bioadhaesiver arzneitraeger zur endothelialen und epithelialen aufnahme und laesionalen lokalisierung therapeutischer und diagnostischer stoffe.
EP88903702A EP0352295B2 (fr) 1987-04-01 1988-03-30 Support de medicaments a bio-adhesion pour absorption endotheliale et epitheliale et localisation d'agents therapeutiques et de diagnostic
DE3881881T DE3881881T3 (de) 1987-04-01 1988-03-30 Bioadhäsiver arzneiträger zur endothelialen und epithelialen aufnahme und läsionalen lokalisierung therapeutischer und diagnostischer stoffe.
CA000565119A CA1324080C (fr) 1987-04-01 1988-04-26 Vecteurs de medicaments bioadhesifs pour absorption endotheliale et epitheliale et transport de l'agent therapeutique ou diagnostic jusqu'a la lesion

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US033,432 1987-04-01
US07/033,432 US4925678A (en) 1987-04-01 1987-04-01 Endothelial envelopment drug carriers
CA000565119A CA1324080C (fr) 1987-04-01 1988-04-26 Vecteurs de medicaments bioadhesifs pour absorption endotheliale et epitheliale et transport de l'agent therapeutique ou diagnostic jusqu'a la lesion

Publications (3)

Publication Number Publication Date
WO1988007365A1 WO1988007365A1 (fr) 1988-10-06
WO1988007365A2 WO1988007365A2 (fr) 1988-10-06
WO1988007365A3 true WO1988007365A3 (fr) 1988-11-17

Family

ID=25671864

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1988/001096 Ceased WO1988007365A2 (fr) 1987-04-01 1988-03-30 Support de medicaments a bio-adhesion pour absorption endotheliale et epitheliale et localisation d'agents therapeutiques et de diagnostic

Country Status (8)

Country Link
US (1) US4925678A (fr)
EP (1) EP0352295B2 (fr)
JP (1) JP2886171B2 (fr)
AT (1) ATE90554T1 (fr)
AU (1) AU607494B2 (fr)
CA (1) CA1324080C (fr)
DE (1) DE3881881T3 (fr)
WO (1) WO1988007365A2 (fr)

Families Citing this family (164)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ217821A (en) * 1985-10-10 1989-07-27 Biotech Australia Pty Ltd Oral delivery system; complex of active agent and vitamin b12 or analogue thereof
US5672334A (en) * 1991-01-16 1997-09-30 Access Pharmaceuticals, Inc. Invivo agents comprising cationic metal chelators with acidic saccharides and glycosaminoglycans
US5707604A (en) * 1986-11-18 1998-01-13 Access Pharmaceuticals, Inc. Vivo agents comprising metal-ion chelates with acidic saccharides and glycosaminoglycans, giving improved site-selective localization, uptake mechanism, sensitivity and kinetic-spatial profiles
US5807832A (en) * 1987-06-09 1998-09-15 Biotech Australia Pty Limited Oral delivery of biologically active substances bound to vitamin B12
WO1990003190A1 (fr) * 1988-09-29 1990-04-05 Ranney David F Procedes et compositions d'imagerie a resonance magnetique
US5260050A (en) * 1988-09-29 1993-11-09 Ranney David F Methods and compositions for magnetic resonance imaging comprising superparamagnetic ferromagnetically coupled chromium complexes
US5213788A (en) * 1988-09-29 1993-05-25 Ranney David F Physically and chemically stabilized polyatomic clusters for magnetic resonance image and spectral enhancement
US5997856A (en) * 1988-10-05 1999-12-07 Chiron Corporation Method and compositions for solubilization and stabilization of polypeptides, especially proteins
US5672683A (en) * 1989-09-07 1997-09-30 Alkermes, Inc. Transferrin neuropharmaceutical agent fusion protein
US5154924A (en) * 1989-09-07 1992-10-13 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
US5977307A (en) * 1989-09-07 1999-11-02 Alkermes, Inc. Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins
US5182107A (en) * 1989-09-07 1993-01-26 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
US6329508B1 (en) 1989-09-07 2001-12-11 Alkermes, Inc. Transferrin receptor reactive chimeric antibodies
US5527527A (en) * 1989-09-07 1996-06-18 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
DE69027941T2 (de) * 1989-11-27 1997-01-23 Nippon Shinyaku Co Ltd Fettemulsion
US5227372A (en) * 1990-03-07 1993-07-13 Children's Medical Center Corporation Method for retaining ophthalmological agents in ocular tissues
US6613306B1 (en) 1990-04-02 2003-09-02 Bracco International B.V. Ultrasound contrast agents and methods of making and using them
US7083778B2 (en) 1991-05-03 2006-08-01 Bracco International B.V. Ultrasound contrast agents and methods of making and using them
IN172208B (fr) * 1990-04-02 1993-05-01 Sint Sa
US6989141B2 (en) 1990-05-18 2006-01-24 Bracco International B.V. Ultrasound contrast agents and methods of making and using them
USRE39146E1 (en) 1990-04-02 2006-06-27 Bracco International B.V. Long-lasting aqueous dispersions or suspensions of pressure-resistant gas-filled microvesicles and methods for the preparation thereof
WO1991016058A1 (fr) * 1990-04-26 1991-10-31 Cytrx Corporation Composition et procede de traitement local de tissus abimes ou malades
US5216130A (en) * 1990-05-17 1993-06-01 Albany Medical College Complex for in-vivo target localization
AU707085B2 (en) * 1991-04-02 1999-07-01 Access Pharmaceuticals Australia Pty Limited Oral delivery systems for microparticles
AU664365B2 (en) * 1991-04-02 1995-11-16 Access Pharmaceuticals Australia Pty Limited Oral delivery systems for microparticles
US5605938A (en) * 1991-05-31 1997-02-25 Gliatech, Inc. Methods and compositions for inhibition of cell invasion and fibrosis using dextran sulfate
US5705178A (en) * 1991-05-31 1998-01-06 Gliatech, Inc. Methods and compositions based on inhibition of cell invasion and fibrosis by anionic polymers
GB9119762D0 (en) * 1991-09-16 1991-10-30 Filler Aaron G Particulate agents for nmt
IL104084A (en) 1992-01-24 1996-09-12 Bracco Int Bv Long-lasting aqueous suspensions of pressure-resistant gas-filled microvesicles their preparation and contrast agents consisting of them
FR2687071B1 (fr) * 1992-02-10 1995-06-23 Exsymol Sa Vecteur pour principe(s) actif(s) therapeutique(s) ou cosmetique(s) a usage externe et composition therapeutique ou cosmetique comprenant un tel vecteur.
US5474765A (en) * 1992-03-23 1995-12-12 Ut Sw Medical Ctr At Dallas Preparation and use of steroid-polyanionic polymer-based conjugates targeted to vascular endothelial cells
AU4693093A (en) * 1992-07-27 1994-02-14 Haemacure Biotech Inc. Biocompatible surgical implant
WO1994003501A1 (fr) * 1992-08-05 1994-02-17 Meito Sangyo Kabushiki Kaisha Composite de petit diametre constitue de carboxypolysaccharide hydrosoluble et d'oxyde de fer magnetique
JPH08506319A (ja) * 1992-10-08 1996-07-09 ヴァレリ ユ． アラホフ ミセル中に組み込まれた抗−新生物性組成物
US5362425A (en) * 1992-10-22 1994-11-08 Technology Unlimited, Inc. Organic oil spray-drying techniques
US5916596A (en) * 1993-02-22 1999-06-29 Vivorx Pharmaceuticals, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
AU6268894A (en) * 1993-02-22 1994-09-14 Alza Corporation Compositions for oral delivery of active agents
US5665382A (en) * 1993-02-22 1997-09-09 Vivorx Pharmaceuticals, Inc. Methods for the preparation of pharmaceutically active agents for in vivo delivery
US6753006B1 (en) 1993-02-22 2004-06-22 American Bioscience, Inc. Paclitaxel-containing formulations
US5997904A (en) * 1993-02-22 1999-12-07 American Bioscience, Inc. Total nutrient admixtures as stable multicomponent liquids or dry powders and methods for the preparation thereof
US5650156A (en) * 1993-02-22 1997-07-22 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of nutriceuticals and compositions useful therefor
US5439686A (en) * 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
DK0693924T4 (da) * 1993-02-22 2008-08-04 Abraxis Bioscience Inc Fremgangsmåde til (in vivo) levering af biologiske materialer og sammensætninger, der er egnede dertil
US6528067B1 (en) 1993-02-22 2003-03-04 American Bioscience, Inc. Total nutrient admixtures as stable multicomponent liquids or dry powders and methods for the preparation thereof
DE59403734D1 (de) * 1993-03-17 1997-09-18 Silica Gel Gmbh Superparamagnetische teilchen, verfahren zu ihrer herstellung und verwendung derselben
GB9312315D0 (en) * 1993-06-15 1993-07-28 Poston Robin Leukocyte adhesion assay
EP0636363B1 (fr) * 1993-07-27 2001-05-23 Terumo Kabushiki Kaisha Système pour la délivrance d'un médicament
DK0711179T3 (da) 1993-07-30 2005-02-14 Imcor Pharmaceutical Co Stabiliserede sammensætninger med mikrobobler til ultralyd
US5798091A (en) 1993-07-30 1998-08-25 Alliance Pharmaceutical Corp. Stabilized gas emulsion containing phospholipid for ultrasound contrast enhancement
US5633003A (en) * 1994-03-31 1997-05-27 Cantor; Jerome O. Use of intratracheally administered hyaluronic acid to ameliorate emphysema
AUPM572294A0 (en) * 1994-05-18 1994-06-09 Vaccine Technologies Pty. Ltd. Delivery vehicle for bioactive molecule
EP0774970A4 (fr) * 1994-08-10 2000-02-02 Roderick T Coward Methode d'utilisation de l'acide hyaluronique pour la detection, la localisation et le diagnostic de tumeurs
FR2723849B1 (fr) 1994-08-31 1997-04-11 Biovector Therapeutics Sa Procede pour augmenter l'immunogenicite, produit obtenu et composition pharmaceutique
US5540909A (en) * 1994-09-28 1996-07-30 Alliance Pharmaceutical Corp. Harmonic ultrasound imaging with microbubbles
US6015555A (en) * 1995-05-19 2000-01-18 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
US5804162A (en) 1995-06-07 1998-09-08 Alliance Pharmaceutical Corp. Gas emulsions stabilized with fluorinated ethers having low Ostwald coefficients
AU6104896A (en) * 1995-06-07 1996-12-30 Regents Of The University Of California, The Therapeutic microdevices and methods of making and using sam e
US6107102A (en) * 1995-06-07 2000-08-22 Regents Of The University Of California Therapeutic microdevices and methods of making and using same
US6106866A (en) * 1995-07-31 2000-08-22 Access Pharmaceuticals, Inc. In vivo agents comprising cationic drugs, peptides and metal chelators with acidic saccharides and glycosaminoglycans, giving improved site-selective localization, uptake mechanism, sensitivity and kinetic-spatial profiles, including tumor sites
CA2235036A1 (fr) 1995-11-08 1997-05-15 University Of South Florida Systeme d'experimentation de leiomyome et d'atherosclerose sur des cobayes
US6423296B1 (en) 1996-01-10 2002-07-23 Amersham Health As Constrast media
GB9600427D0 (en) * 1996-01-10 1996-03-13 Nycomed Imaging As Contrast media
US5855868A (en) * 1996-04-01 1999-01-05 Nycomed Imaging As Method of T1 -weighted resonance imaging of RES organs
DE69733664T3 (de) 1996-04-19 2011-04-14 Grifols Inc. (n.d. Ges.d.Staates Delaware), Los Angeles Verfahren zur INaktivierung von Viren und Lyophilisierung von Blutproteinen
EP1369111A1 (fr) * 1996-10-03 2003-12-10 Hermes Biosciences, Inc. Microparticules hydrophiles et leurs procédés de préparation
US6096291A (en) * 1996-12-27 2000-08-01 Biovector Therapeutics, S.A. Mucosal administration of substances to mammals
WO1999012571A1 (fr) * 1997-09-05 1999-03-18 Maruho Kabushikikaisha Preparations de nanocapsules destinees au traitement de maladies intra-articulaires
US6489306B2 (en) 1998-02-23 2002-12-03 University Of South Florida Method of intranasal gene transfer for protection against respiratory infection
US6028102A (en) * 1998-02-24 2000-02-22 Yissum Research Development Company Of The Hebrew University Of Jerusalem Anticonvulsant drugs and pharmaceutical compositions thereof
US6338834B1 (en) 1998-04-30 2002-01-15 The Curators Of The University Of Missouri Melanotropin analogs for potential radiopharmaceuticals for diagnosis and treatment of melanoma
US6391861B1 (en) 1998-05-14 2002-05-21 The Trustees Of Columbia University In The City Of New York Method for the prevention of tissue elastic fiber injury
US6344443B1 (en) 1998-07-08 2002-02-05 University Of South Florida Peptide antagonists of tumor necrosis factor alpha
US7605149B1 (en) 1998-07-13 2009-10-20 University Of South Florida Modulation of the phospholipase A2 pathway as a therapeutic
AU5329599A (en) * 1998-07-30 2000-02-21 University Of South Florida Method for the modulation of function of transcription factors
US6780397B2 (en) 1998-09-01 2004-08-24 Curators Of The University Of Missouri Biomolecule conjugation strategy using novel water-soluble phosphine-based chelating agents
US6299980B1 (en) 1998-09-29 2001-10-09 Medtronic Ave, Inc. One step lubricious coating
US6379691B1 (en) 1998-09-29 2002-04-30 Medtronic/Ave, Inc. Uses for medical devices having a lubricious, nitric oxide-releasing coating
US6409987B1 (en) 1999-04-07 2002-06-25 Intimax Corporation Targeted agents useful for diagnostic and therapeutic applications
US6638974B1 (en) 1999-04-09 2003-10-28 University Of South Florida Ascorbyl esters for the treatment of cancer
US6787318B1 (en) * 1999-06-01 2004-09-07 Roskamp Research Institute, Llc Assay for evaluating the therapeutic effectiveness of agents in reducing Alzheimer's disease pathology
ES2313895T3 (es) * 1999-06-14 2009-03-16 Henry Ford Health System Donadores de oxido nitrico para inducir neurogenesis.
US7135498B1 (en) 1999-06-14 2006-11-14 Henry Ford Health System Nitric oxide donors for inducing neurogenesis
US7655423B2 (en) * 1999-06-14 2010-02-02 Henry Ford Health System Nitric oxide donors for inducing neurogenesis
US6998232B1 (en) 1999-09-27 2006-02-14 Quark Biotech, Inc. Methods of diagnosing bladder cancer
US6462066B2 (en) 1999-12-02 2002-10-08 University Of South Florida Method and composition for treatment of ischemic neuronal reperfusion injury
JP2004513071A (ja) * 2000-05-23 2004-04-30 ザ・トラスティーズ・オブ・コロンビア・ユニバーシティ・イン・ザ・シティ・オブ・ニューヨーク 肺の弾性繊維損傷に関連した呼吸器疾患の治療方法
US20020022594A1 (en) * 2000-07-11 2002-02-21 Ping Dou Bax fragment induced tumor cell death
US6803060B2 (en) 2000-09-07 2004-10-12 Joe Reyes Composition to boost libido
US20070031372A1 (en) * 2004-08-05 2007-02-08 Hadden John W Vaccine immunotherapy for immune suppressed patients
US20070025958A1 (en) 2000-10-27 2007-02-01 Hadden John W Vaccine immunotherapy
US20060194242A1 (en) * 2000-10-27 2006-08-31 Hadden John W Immunotherapy for immune suppressed patients
US20070154399A1 (en) * 2000-10-27 2007-07-05 Hadden John W Immunotherapy for immune suppressed patients
CA2950109C (fr) * 2000-10-27 2019-02-19 John W. Hadden Immunotherapie vaccinale pour patients immunodeprimes
US7182942B2 (en) * 2000-10-27 2007-02-27 Irx Therapeutics, Inc. Vaccine immunotherapy for immune suppressed patients
US20020146409A1 (en) * 2001-01-30 2002-10-10 Herring Steven W. Methods for stabilizing lyophilized blood proteins
US7172770B2 (en) * 2001-02-19 2007-02-06 Board Of Regents, The University Of Texas System Mesoporous compositions for use in drug delivery
US6770622B2 (en) 2001-06-08 2004-08-03 Gary A. Jarvis N-terminally truncated galectin-3 for use in treating cancer
WO2003035004A2 (fr) 2001-10-26 2003-05-01 Immuno-Rx, Inc. Immunotherapie de retablissement d'immunite supprimee
EP1389487B1 (fr) * 2002-07-16 2006-05-03 Seiko Epson Corporation Composition contenant des microcapsules pour écrans électrophorétiques
US20040146949A1 (en) * 2002-10-25 2004-07-29 Jun Tan Methods and compounds for disruption of CD40R/CD40L signaling in the treatment of alzheimer's disease
EP1662879A4 (fr) * 2003-08-29 2009-03-11 Univ New York Administration indirecte de facteurs de croissance dans le systeme nerveux central
AU2004279314B2 (en) * 2003-09-12 2010-12-09 The Regents Of The University Of Colorado, A Body Corporate Glutamine for use in treating injury
WO2005059100A2 (fr) * 2003-12-12 2005-06-30 New York University Procedes et compositions se rapportant a la cystatine c
EP1758998B1 (fr) 2004-01-30 2010-12-15 Quark Pharmaceuticals, Inc. Oligoribonucleotides et procedes d'utilisation de ceux-ci dans le traitement d'etats fibreux et d'autres maladies
US7741299B2 (en) 2004-08-16 2010-06-22 Quark Pharmaceuticals, Inc. Therapeutic uses of inhibitors of RTP801
JPWO2006035550A1 (ja) * 2004-09-28 2008-05-15 国立大学法人大阪大学 三次元誘導装置及び方法、並びに薬剤配送システム
MX2007003795A (es) 2004-09-28 2007-07-11 Quark Biotech Inc Oligoribonucleotidos y metodos de uso de los mismos para tratamiento de la alopecia, insuficiencia renal aguda y otras enfermedades.
EP1981910B1 (fr) 2006-01-13 2013-06-26 A Chan Holding B.V. Méthode d'identification d'un inhibiteur de l'interaction entre le glypican et la sclerostine
NL2000439C2 (nl) 2006-01-20 2009-03-16 Quark Biotech Therapeutische toepassingen van inhibitoren van RTP801.
US20080260678A1 (en) * 2006-10-10 2008-10-23 University Of Colorado Molecular band-aid
JP2010507387A (ja) 2006-10-25 2010-03-11 クアーク・ファーマスーティカルス、インコーポレイテッド 新規のｓｉＲＮＡおよびその使用方法
US8729121B2 (en) 2007-06-25 2014-05-20 Adhezion Biomedical, Llc Curing accelerator and method of making
HRP20140522T1 (hr) 2007-06-27 2014-08-15 Quark Pharmaceuticals, Inc. Pripravci i metode za inhibiranje izražaja proapoptotiäśkih gena
BRPI0817605A2 (pt) 2007-10-03 2017-05-09 Quark Pharmaceuticals Inc novas estruturas de sirna
US8613952B2 (en) * 2007-11-14 2013-12-24 Adhezion Biomedical, Llc Cyanoacrylate tissue adhesives
US8486528B2 (en) * 2008-01-22 2013-07-16 Gwangju Institute Of Science And Technology Temperature-sensitive nano-carriers
EP2106791A1 (fr) 2008-03-31 2009-10-07 Biotempt B.V. Glutamine ou dipeptide contenant de la glutamine avec une posologie spécifique pour le traitement des inflammations
US8293838B2 (en) * 2008-06-20 2012-10-23 Adhezion Biomedical, Llc Stable and sterile tissue adhesive composition with a controlled high viscosity
US8198344B2 (en) 2008-06-20 2012-06-12 Adhezion Biomedical, Llc Method of preparing adhesive compositions for medical use: single additive as both the thickening agent and the accelerator
US20110117047A1 (en) 2008-06-23 2011-05-19 Adhezion Biomedical, Llc Cyanoacrylate tissue adhesives with desirable permeability and tensile strength
US9254133B2 (en) 2008-10-31 2016-02-09 Adhezion Biomedical, Llc Sterilized liquid compositions of cyanoacrylate monomer mixtures
US8609128B2 (en) * 2008-10-31 2013-12-17 Adhezion Biomedical, Llc Cyanoacrylate-based liquid microbial sealant drape
US8652510B2 (en) 2008-10-31 2014-02-18 Adhezion Biomedical, Llc Sterilized liquid compositions of cyanoacrylate monomer mixtures
US20110288155A1 (en) 2008-12-18 2011-11-24 Elena Feinstein Sirna compounds and methods of use thereof
WO2010111598A1 (fr) 2009-03-26 2010-09-30 Henry Ford Health System Procédés pour améliorer l'évolution neurologique après une lésion neurale et une maladie neurodégénérative
US8637482B2 (en) 2009-06-08 2014-01-28 Quark Pharmaceuticals, Inc. Methods for treating chronic kidney disease
WO2011066475A1 (fr) 2009-11-26 2011-06-03 Quark Pharmaceuticals, Inc. Composés d'arnsi comportant des substitutions terminales
EP3012324A3 (fr) 2009-12-09 2016-07-06 Nitto Denko Corporation Modulation de l'expression hsp47
EP2862929B1 (fr) 2009-12-09 2017-09-06 Quark Pharmaceuticals, Inc. Compositions et procédés pour le traitement de maladies, troubles ou lésions du système nerveux central
WO2011084193A1 (fr) 2010-01-07 2011-07-14 Quark Pharmaceuticals, Inc. Composés oligonucléotidique comportant des extrémités sortantes non nucléotidiques
CA2827401A1 (fr) 2010-02-22 2011-08-25 Health Enhancement Products, Inc. Agents et mecanismes de traitement de l'hypercholesterolemie
US9309019B2 (en) 2010-05-21 2016-04-12 Adhezion Biomedical, Llc Low dose gamma sterilization of liquid adhesives
CA2801928C (fr) 2010-06-24 2018-04-10 Quark Pharmaceuticals, Inc. Composes a base d'arn double brin pour le gene rhoa et leur utilisation
US20140134231A1 (en) 2010-10-11 2014-05-15 Sanford-Burnham Medical Research Institute Mir-211 expression and related pathways in human melanoma
CA2818024C (fr) 2010-12-06 2019-09-24 Quark Pharmaceuticals, Inc. Composes oligonucleotidiques a double brin comprenant des modifications de position
US9205100B2 (en) 2011-03-03 2015-12-08 Quark Pharmaceuticals, Inc. Compositions and methods for treating lung disease and injury
AU2012223366B2 (en) 2011-03-03 2017-02-23 Quark Pharmaceuticals, Inc. Oligonucleotide modulators of the toll-like receptor pathway
WO2013003697A1 (fr) 2011-06-30 2013-01-03 Trustees Of Boston University Méthode de régulation de croissance tumorale, d'angiogenèse et de métastase à l'aide du récepteur 1 riche en proline et contenant une immunoglobuline (igpr-1)
WO2013070821A1 (fr) 2011-11-08 2013-05-16 Quark Pharmaceuticals, Inc. Méthodes et compositions destinées à traiter des maladies, des troubles ou une lésion du système nerveux
SG11201403756PA (en) 2012-01-01 2014-11-27 Qbi Entpr Ltd Endo180-targeted particles for selective delivery of therapeutic and diagnostic agents
BR112014016937A2 (pt) 2012-01-12 2017-06-13 Quark Pharmaceuticals Inc terapia de combinação para o tratamento de desordens de audição e do equilíbrio
US20130315891A1 (en) 2012-05-25 2013-11-28 Matthew Charles Formulations of human tissue kallikrein-1 for parenteral delivery and related methods
HRP20170673T1 (hr) 2012-06-04 2017-07-14 Diamedica Inc. Glikozilacijske izoforme kalikreina 1 iz ljudskog tkiva
ES2651113T3 (es) 2012-06-25 2018-01-24 The Brigham And Women's Hospital, Inc. Tratamientos terapéuticos dirigidos
WO2014043291A1 (fr) 2012-09-12 2014-03-20 Quark Pharmaceuticals, Inc. Composés d'acide nucléique double brin
AU2013315524B2 (en) 2012-09-12 2019-01-31 Quark Pharmaceuticals, Inc. Double-stranded oligonucleotide molecules to p53 and methods of use thereof
ES2872349T3 (es) 2012-09-12 2021-11-02 Quark Pharmaceuticals Inc Moléculas de oligonucleótidos bicatenarios para DDIT4 y métodos de uso de las mismas
CA2893427C (fr) 2012-12-24 2023-01-10 Neurogastrx, Inc. Methodes de traitement d'affections du tractus digestif
KR20160029731A (ko) 2013-03-12 2016-03-15 더 제너럴 하스피탈 코포레이션 변형된 뮐러관 억제 물질(mis) 단백질 및 질환 치료를 위한 그 용도
WO2014142938A1 (fr) * 2013-03-15 2014-09-18 Aihol Corporation Formulation pharmaceutique contenant un glycosaminoglycane
US9539265B2 (en) 2013-03-15 2017-01-10 Aihol Corporation Pharmaceutical formulation containing glycosaminoglycan
US10232028B2 (en) 2013-06-13 2019-03-19 Zivo Bioscience, Inc. Compounds and methods for affecting cytokines
WO2015020960A1 (fr) 2013-08-09 2015-02-12 Novartis Ag Nouveaux polynucléotides longs arn non codants (arn lnc)
AU2014362307A1 (en) 2013-12-11 2016-06-30 The General Hospital Corporation Use of mullerian inhibiting substance (MIS) proteins for contraception and ovarian reserve preservation
US9421297B2 (en) 2014-04-02 2016-08-23 Adhezion Biomedical, Llc Sterilized compositions of cyanoacrylate monomers and naphthoquinone 2,3-oxides
US9844554B2 (en) 2014-06-24 2017-12-19 Neurogastrx, Inc. Prodrugs of metopimazine
BR112017017599B1 (pt) 2015-02-16 2021-11-16 Zivo Bioscience, Inc. Usos de uma biomassa algal ou de um sobrenadante derivado de ao menos uma espécie de algas klebsormidium
CA3014897C (fr) 2016-02-16 2020-12-29 Zivo Bioscience, Inc. Soutien nutritionnel d'animaux par administration d'un supplement a base d'algues
EP3592377A4 (fr) 2017-03-09 2021-02-17 Diamedica Inc. Formes posologiques de kallicréine tissulaire 1
US10836757B1 (en) 2020-04-02 2020-11-17 Neurogastrx, Inc. Polymorphic forms of metopimazine
EP3922720A1 (fr) 2020-06-09 2021-12-15 Universidad de Murcia Thérapie pour empêcher un remodelage cardiaque indésirable après un infarctus aigu du myocarde
US20220265582A1 (en) 2021-02-24 2022-08-25 Universitätsspital Basel Effects of mescaline and of mescaline analogs (scalines) to assist psychotherapy
US11801256B2 (en) 2021-06-08 2023-10-31 Universitätsspital Basel Antidepressant-psilocybin co-treatment to assist psychotherapy
CA3228975A1 (fr) 2021-08-19 2023-02-23 Peter Mack Formulations a liberation immediate de diethylamide de l'acide d-lysergique pour des applications therapeutiques

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1516348A (en) * 1974-09-18 1978-07-05 Pharma Soc Of Victoria Injectable compositions
GB2041517A (en) * 1979-01-09 1980-09-10 Fuji Photo Film Co Ltd Material and process for immunological assay
EP0087786A1 (fr) * 1982-02-28 1983-09-07 Yeda Research And Development Company, Ltd. Perles d'agarose et de polyaldéhydes, procédé pour leur préparation et leur usage
CA1168150A (fr) * 1981-12-18 1984-05-29 The Governors Of The University Of Alberta Conjugats d'albumine et d'agents therapeutiques
EP0167825A2 (fr) * 1984-06-08 1986-01-15 Dr. Rentschler Arzneimittel GmbH & Co. Nanobilles lipidiques comme véhicule pour médicaments destinés à l'administration orale
GB2185397A (en) * 1986-01-17 1987-07-22 Cosmas Damian Ltd Drug delivery system
EP0240424A1 (fr) * 1986-03-28 1987-10-07 Universite De Rennes I Nanoparticules à base de polymère ou copolymère méthacrylique, procédé de préparation, et application comme vecteur de médicament

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2374910A1 (fr) * 1976-10-23 1978-07-21 Choay Sa Preparation a base d'heparine, comprenant des liposomes, procede pour l'obtenir et medicaments contenant de telles preparations
US4182330A (en) * 1977-07-25 1980-01-08 Alza Corporation Means for administering amphipathic medicament
CS216992B1 (en) * 1980-07-21 1982-12-31 Miroslav Stol Composite polymere material for the biological and medicinal utilitation and method of preparation thereof
JPS57130914A (en) * 1981-02-04 1982-08-13 Agency Of Ind Science & Technol Prolongation of activity retention
SE8204244L (sv) * 1982-07-09 1984-01-10 Ulf Schroder Kristalliserad kolhydratsmatris for biologiskt aktiva substanser
US4671958A (en) * 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
SE8201972L (sv) * 1982-03-29 1983-09-30 Gambro Lundia Ab Magnetiskt paverkbara kristalliserade kolhydrat sferer eller partiklar att anvendas tillsammans med bioadsorberande material
US4624846A (en) * 1983-07-29 1986-11-25 Immunomedics, Inc. Method for enhancing target specificity of antibody localization and clearance of non-target diagnostic and therapeutic principles
US4568536A (en) * 1985-02-08 1986-02-04 Ethicon, Inc. Controlled release of pharmacologically active agents from an absorbable biologically compatible putty-like composition

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1516348A (en) * 1974-09-18 1978-07-05 Pharma Soc Of Victoria Injectable compositions
GB2041517A (en) * 1979-01-09 1980-09-10 Fuji Photo Film Co Ltd Material and process for immunological assay
CA1168150A (fr) * 1981-12-18 1984-05-29 The Governors Of The University Of Alberta Conjugats d'albumine et d'agents therapeutiques
EP0087786A1 (fr) * 1982-02-28 1983-09-07 Yeda Research And Development Company, Ltd. Perles d'agarose et de polyaldéhydes, procédé pour leur préparation et leur usage
EP0167825A2 (fr) * 1984-06-08 1986-01-15 Dr. Rentschler Arzneimittel GmbH & Co. Nanobilles lipidiques comme véhicule pour médicaments destinés à l'administration orale
GB2185397A (en) * 1986-01-17 1987-07-22 Cosmas Damian Ltd Drug delivery system
EP0240424A1 (fr) * 1986-03-28 1987-10-07 Universite De Rennes I Nanoparticules à base de polymère ou copolymère méthacrylique, procédé de préparation, et application comme vecteur de médicament

Also Published As

Publication number Publication date
EP0352295B1 (fr) 1993-06-16
AU1627588A (en) 1988-11-02
DE3881881D1 (de) 1993-07-22
AU607494B2 (en) 1991-03-07
ATE90554T1 (de) 1993-07-15
CA1324080C (fr) 1993-11-09
JP2886171B2 (ja) 1999-04-26
US4925678A (en) 1990-05-15
EP0352295A1 (fr) 1990-01-31
WO1988007365A2 (fr) 1988-10-06
EP0352295B2 (fr) 1996-04-10
DE3881881T2 (de) 1993-12-16
DE3881881T3 (de) 1997-06-05
JPH04504404A (ja) 1992-08-06

Similar Documents

Publication Publication Date Title
WO1988007365A3 (fr) Support de medicaments a bio-adhesion pour absorption endotheliale et epitheliale et localisation d'agents therapeutiques et de diagnostic
Danon et al. Promotion of wound repair in old mice by local injection of macrophages.
US5814599A (en) Transdermal delivery of encapsulated drugs
ES2056832T3 (es) Un vehiculo de liberacion para un ingrediente activo.
ATE107858T1 (de) Pharmazeutische zusammensetzung zum abnehmen.
Parsons et al. Initial fall of plasma calcium after intravenous injection of parathyroid hormone
CO5261582A1 (es) Composiciones de valdecoxib
HK1044290A1 (zh) X射線引導的藥物輸送
EP2298310A3 (fr) Inhibiteur thérapeutique de cellules de muscles vasculaires lisses
CA2382143A1 (fr) Procede, reactif et cartouche d'essai destines a determiner le temps de coagulation
Montana et al. Topical application of WR‐2721 to prevent radiation‐induced proctosigmoiditis. A phase I/II trial
SK42395A3 (en) Pharmaceutical agent for treatment or prevention of insulin-dependent diabetes mellitus, a method of producing and use thereof
Taal et al. Improved effect of 131I-MIBG treatment by predosing with non-radiolabeled MIBG in carcinoid patients, and studies in xenografted mice
EP0393707A3 (fr) Composés bio-actifs associés à des liposomes et leur utilisation dans des préparations pharmaceutiques
Pattanapanyasat et al. Effect of orally active hydroxypyridinone iron chelators on human lymphocyte function
Gross et al. Disseminated Cryptococcus treated with transfer factor
Weide et al. Study of immune function of cancer patients influenced by supplemental zinc or selenium-zinc combination
Elbaum et al. Bullae in a patient with toxic shock syndrome
Lupera et al. Phase II trial of combination chemotherapy with dacarbazine, cyclophosphamide, cisplatin, doxorubicin, and vindesine (DECAV) in advanced renal cell cancer
FI885797A7 (fi) Peptidejä, menetelmä niiden valmistamiseksi, niiden käyttö vasta-aineiden valmistamiseksi, sekä näiden käyttö ihmisen veren PAI-1-aktiivisuuden estämiseksi
Ernst et al. In vitro susceptibility testing and the outcome of treatment of infection.
McCue et al. A proposed short form of the Luria-Nebraska Neuropsychological Battery oriented toward assessment of the elderly.
JP2000501093A (ja) β―インターフェロンを使用して再狭窄を治療する方法
Domb et al. Methotrexate polymer implant for the treatment of head and neck cancer
Gryglewski et al. Bioassay of histamine in the presence of prostaglandins

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AT AU BB BG BR CH DE DK FI GB HU JP KP KR LK LU MC MG MW NL NO RO SD SE SU US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE BJ CF CG CH CM DE FR GA GB IT LU ML MR NL SE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AT AU BB BG BR CH DE DK FI GB HU JP KP KR LK LU MC MG MW NL NO RO SD SE SU

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE BJ CF CG CH CM DE FR GA GB IT LU ML MR NL SE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 1988903702

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1988903702

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 1988903702

Country of ref document: EP